U.S., Jan. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07365358) titled 'Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients' on Jan. 15.
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Diabete Type 2
Intervention:
DRUG: empagliflozin 10mg
once a day for 24 weeks
DRUG: Glimepiride 1mg
once a day for 24 weeks
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Chong Kun Dang Pharmaceutical
Published by HT Digital Content Services with permissi...